Medical Science Liaison (MSL) – North Central
Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company, is a clinical-stage company developing orexin receptor 2 (OX2R) agonists as a new class of medicines for the treatment of narcolepsy and potentially other sleep-wake disorders. Centessa’s lead investigational candidate – cleminorexton (formerly ORX750) – is being developed for narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia. Centessa's OX2R agonist portfolio includes additional clinical and preclinical-stage assets with potential utility across a broader range of neurological, neurodegenerative, and neuropsychiatric conditions.
Headquartered in Boston, Massachusetts, Centessa was recognized as a Great Place to Work® in 2026.
Description of Role
The MSL will serve as a field-based scientific expert responsible for engaging with healthcare professionals (HCPs), supporting clinical development, and ensuring alignment with Centessa’s strategic medical objectives. This role is critical in translating complex scientific data into meaningful clinical insights and fostering compliant, evidence-based dialogue with thought leaders.
Key Responsibilities
<
